Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03201575
Other study ID # 69HCL17_0290
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 28, 2017
Est. completion date August 12, 2019

Study information

Verified date July 2022
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Septic shock remains a major public health problem in industrialized countries, with a mortality rate as high as 50%, largely related to multiple organ dysfunction. In addition to dysregulated inflammatory response, the pathophysiology of organ failures in septic shock involves ischemia-reperfusion processes. Remote ischemic conditioning is a therapeutic strategy for protecting organs against the detrimental effects of ischemia-reperfusion injury. The objective of the present study is to determine whether remote ischemic conditioning can limit the severity of organ failure in patients with septic shock.


Recruitment information / eligibility

Status Completed
Enrollment 180
Est. completion date August 12, 2019
Est. primary completion date August 12, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years - Hospitalization in an intensive care unit for less than 24 hours - Septic shock evolving for less than 12 hours defined as: - Documented or suspected infection - Norepinephrine administration to maintain a mean arterial pressure = 65 mmHg after volemia correction - Lactatemia > 2 mmol/L at least once in the past 12 hours before inclusion - Written informed consent signed by the patient or by a next of kin or oral consent given by the patient and as soon as permitted by the clinical state written informed consent signed by the patient. Exclusion Criteria: - Patient who has expressed the wish not to be resuscitated - Contraindication of the use of brachial cuff on both arms - Intercurrent pathology with an expected life expectancy of less than 24 hours - Cardiac arrest - Female patients currently pregnant or women of childbearing age who are not using contraception - Previous inclusion in RECO-Sepsis study - Previous inclusion in another clinical study - Patients without health coverage

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Remote Ischemic conditioning
A brachial cuff is positioned around the arm of the patient. Four cycles of [5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation] started as soon as possible after randomization. The intervention is repeated at 12 and 24 hours after inclusion.
Patients with no remote ischemic conditioning
A brachial cuff is positioned around the arm of the patient and no inflation or deflation is made.

Locations

Country Name City State
France CHU de Clermont-Ferrand Clermont-Ferrand
France CHU de Grenoble Grenoble
France Hôpital Edouard Herriot Lyon
France CHU de Montpellier Montpellier
France CH de Roanne Roanne
France CHU de Saint-Etienne Saint-Étienne

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Average SOFA score (Sequential Organ Failure Assessment) The SOFA score ranges from 0 to 24 (higher scores indicate more severe organ failure), with 0 to 4 points assigned for each of 6 organ dysfunctions (ie, central nervous system, cardiovascular, respiratory, renal, coagulation, and liver). 96 hours.
Secondary Average SOFA score without the neurologic sub-score. The SOFA score without the neurologic subscore ranges from 0 to 20 (higher scores indicate more severe organ failure), with 0 to 4 points assigned for each of 5 organ dysfunctions (ie, cardiovascular, respiratory, renal, coagulation, and liver). 96 hours.
Secondary SOFA score. 24 hours
Secondary SOFA score. 48 hours
Secondary SOFA score. 72 hours
Secondary SOFA score. 96 hours
Secondary Variations of SOFA score (delta-SOFA) 24 hours
Secondary SOFA sub-scores for each organs 48 hours
Secondary SOFA sub-scores for each organs 72 hours
Secondary SOFA sub-scores for each organs 96 hours
Secondary Survival without organ support Day 28
Secondary Intensive care unit (ICU) length of stay. Day 90
Secondary Hospital length of stay Day 90
Secondary All-cause mortality Day 90
See also
  Status Clinical Trial Phase
Recruiting NCT03649633 - Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock Phase 1/Phase 2
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Completed NCT05629780 - Temporal Changes of Lactate in CLASSIC Patients N/A
Recruiting NCT04796636 - High-dose Intravenous Vitamin C in Patients With Septic Shock Phase 1
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Recruiting NCT05066256 - LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Recruiting NCT02899143 - Short-course Antimicrobial Therapy in Sepsis Phase 2
Recruiting NCT02676427 - Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination
Recruiting NCT02580240 - Administration of Hydrocortisone for the Treatment of Septic Shock N/A
Recruiting NCT02565251 - Volemic Resuscitation in Sepsis and Septic Shock N/A
Not yet recruiting NCT02547467 - TOADS Study: TO Assess Death From Septic Shock. N/A
Terminated NCT02335723 - ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber N/A
Completed NCT02638545 - Hemodynamic Effects of Dexmedetomidine in Septic Shock Phase 3
Completed NCT02306928 - PK Analysis of Piperacillin in Septic Shock Patients N/A
Completed NCT02204852 - Co-administration of Iloprost and Eptifibatide in Septic Shock Patients Phase 2